Minjuvi (Tafasitamab)

Tafasitamab, the active ingredient in Minjuvi, is a monoclonal antibody presented as an intravenous formulation for intravenous use. It selectively binds the CD19 antigen on malignant B‑cells and is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma, typically in combination with lenalidomide.

GNH USA supplies Minjuvi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation, cold‑chain logistics where required, and responsive technical support to ensure safe and reliable product delivery.

Minjuvi (taf... ) is used in the treatment of B‑cell malignancies, specifically diffuse large B‑cell lymphoma. - Relapsed diffuse large B‑cell lymphoma (DLBCL): improves overall response rates when combined with lenalidomide. - Refractory diffuse large B‑cell lymphoma (DLBCL): provides an additional therapeutic option for patients who have failed prior regimens. - Combination therapy with lenalidomide: enhances antibody‑dependent cellular cytotoxicity against CD19‑positive lymphoma cells.

Tafasitamab may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Infusion‑related reactions (fever, chills, flushing). - Fatigue or weakness. - Nausea or vomiting. - Headache. - Diarrhea. - Decreased appetite. Serious or Rare Side Effects: - Severe infections (including opportunistic infections). - Hepatic toxicity (elevated transaminases, hepatitis). - Anaphylaxis or severe hypersensitivity reactions. - Tumor lysis syndrome. - Cytopenias (neutropenia, thrombocytopenia).

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Infusion monitoring: observe for reactions during and after administration. - Hepatic function: evaluate liver enzymes prior to treatment and periodically thereafter. - Infection risk: screen for active infections and vaccinate appropriately before therapy. - Hypersensitivity: avoid in patients with known allergy to tafasitamab or its excipients. - Pregnancy and lactation: use only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tafasitamab may interact with other agents that affect immune function or increase infection risk. Major Interactions (Avoid): - Concurrent use of other monoclonic antibodies (e.g., rituximab) due to additive immunosuppression. - Live vaccines during treatment (risk of vaccine‑derived infection). - Strong immunosuppressants (e.g., high‑dose steroids) that may diminish efficacy. Moderate Interactions (Monitor Closely): - Lenalidomide: requires coordinated dosing and safety monitoring. - Anticoagulants: monitor for bleeding if thrombocytopenia develops. - Hepatotoxic drugs: watch liver function tests. - Vaccinations (non‑live): schedule before therapy when possible.